A Real-world study on treatment persistence with Golimumab in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in French clinical practice.

Trial Profile

A Real-world study on treatment persistence with Golimumab in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in French clinical practice.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms GO-PRACTICE
  • Most Recent Events

    • 07 Jul 2017 New trial record
    • 17 Jun 2017 Results (n=228) of interim analysis assessing persistence of Golimumab at 1 year, presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top